Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies.
2021
Keywords:
-
Correction
-
Source
-
Cite
-
Save
6
References
4
Citations
NaN
KQI